Reactome | lorlatinib-resistant ALK mutants

Schema > Pathway > Entries

lorlatinib-resistant ALK mutants Show undefined attributes

authored	[InstanceEdit:9724129] Rothfels, Karen, 2021-03-22
compartment	[Compartment:70101] cytosol [Compartment:876] plasma membrane
created	[InstanceEdit:9717328] Rothfels, Karen, 2021-03-08
crossReference	[DatabaseIdentifier:12020745] Mondo:0004992
dbId	9717329
disease	[Disease:1500689] cancer
displayName	lorlatinib-resistant ALK mutants
edited	[InstanceEdit:9725664] Rothfels, Karen, 2021-03-30
eventOf	[Pathway:R-HSA-9700649] Drug resistance of ALK mutants - Homo sapiens
hasDiagram	true
hasEHLD	false
hasEvent	[FailedReaction:R-HSA-9715355] lorlatinib-resistant ALK mutants don't bind lorlatinib - Homo sapiens
isInDisease	true
isInferred	false
literatureReference	[LiteratureReference:9713962] Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer [LiteratureReference:9714001] Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer [LiteratureReference:9699768] Role and targeting of anaplastic lymphoma kinase in cancer [LiteratureReference:9717312] Targeting ALK: Precision Medicine Takes on Drug Resistance [LiteratureReference:9717307] Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
maxDepth	2
modified	[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	lorlatinib-resistant ALK mutants
normalPathway	[Pathway:R-HSA-201556] Signaling by ALK
releaseDate	2021-06-09
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9729891] Inghirami, Giorgio, 2021-05-04
schemaClass	Pathway
species	[Species:48887] Homo sapiens
stId	R-HSA-9717329
summation	[Summation:9717298] Lorlatinib is a third generation tyrosine kinase inhibitor w...

Referrals

(hasEvent)

[Pathway:R-HSA-9700649] Drug resistance of ALK mutants

Cite Us!